** Jazz Pharmaceuticals' JAZZ.O shares rise 3% to $141.29
** Brokerage Morgan Stanley raises PT to $183 from $175, a 34.1% upside to the stock's last close; maintains "overweight" rating
** Says growth of Jazz's newer sleep disorder drug Xywav in H1 should offset ongoing switch from older drug Xyrem
** Sees 'meaningful expansion' opportunity for Jazz's breast cancer drug Ziihera
** Brokerage expects peak annual revenue of $240 million for brain tumor drug dordaviprone, Jazz's newly acquired drug from its buyout of Chimerix CMRX.O
** Six brokerages rate the stock "buy" or equivalent, one "neutral"; their median PT is $187.47, according to data compiled by LSEG
** JAZZ has risen 16.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.